Immatics (IMTX) delivered earnings and revenue surprises of -18.37% and -22.12%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Immatics (IMTX) delivered earnings and revenue surprises of -18.37% and -22.12%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Immatics (IMTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CG Oncology, Inc. (CGON) delivered earnings and revenue surprises of +25.58% and +48.52%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Bristol Myers (BMY) delivered earnings and revenue surprises of +11.57% and +4.07%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Nasdaq: NYAX rose 13.9% on Tuesday after announcing acquisition of IPS Group Inc. for $350 million. Other big gainers include CAPR, RZLV, CRML, and MAIR.read more...
Immatics (IMTX) delivered earnings and revenue surprises of -19.05% and -38.95%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
MDGL stock up on better-than-expected first-quarter results on account of robust Rezdiffra sales, driven by strong MASH demand and rising patient adoption.